



THE MYELODYSPLASTIC SYNDROMES FOUNDATION

BOARD OF DIRECTORS

John M. Bennett, MD
University of Rochester
Rochester, New York, USA

David T. Bowen, MD
University of Dundee Medical School
Dundee Teaching Hospital
Dundee, Scotland

Theo J.M. de Witte, MD, PhD
University of Nijmegen
University Hospital St. Radboud
Nijmegen, The Netherlands

Peter L. Greenberg, MD
Stanford University School of Medicine
Stanford, California, USA

**Terry Hamblin, DM,
FRCP, FRC Path**
Southampton University
Bournemouth, United Kingdom

Eva Hellström-Lindberg, MD, PhD
Karolinska Institute at
Huddinge University Hospital
Stockholm, Sweden

Kathy Heptinstall, BSN, RN
Operating Director
The MDS Foundation

Alan F. List, MD
University of South Florida
Tampa, Florida, USA

G.J. Mufti, MD
School of Medicine and Dentistry of
King's College London
London, United Kingdom

Charlotte M. Niemeyer, MD
University Children's Hospital
Freiburg, Germany

Stephen D. Nimer, MD
Weill Medical College of
Cornell University
New York, New York, USA

Hussain I. Saba, MD, PhD
University of South Florida
Tampa, Florida, USA

Franz Schmalzl, MD
University Hospital of Innsbruck
Innsbruck, Austria

Robert J. Weinberg, Esq.
Pepper Hamilton LLP
Philadelphia, Pennsylvania, USA

June 30, 2004

Uwe Platzbecker, MD
Universitätsklinikum Carl Gustav Carus
Fetscherstraße 74
01307 Dresden
Germany

Dear Dr. Platzbecker:

On behalf of the Myelodysplastic Syndromes Foundation we congratulate the Universitätsklinikum Carl Gustav Carus on achieving recognition as a Center of Excellence in the research, diagnosis, and treatment of MDS.

The Foundation looks forward to working with you and the Universitätsklinikum Carl Gustav Carus to further worldwide research efforts, provide excellence in diagnosis, treatment, and supportive care for patients, and to extend education about MDS not only to the hematology/oncology physician community but to patients and families of patients and as well as to the general public.

Thank you for participating in this program and for allowing the Foundation to provide referrals for patients from within your geographic region to your Center. Thank you as well as providing patients for the International Patient Registry. Both of these programs are very important to patients and to ongoing research in MDS.

Sincerely,

John M. Bennett, M.D.

John M. Bennett, Chairman
The Myelodysplastic Syndromes Foundation

JMB/lac